1159835-31-0 Usage
Description
1-(tert-butoxycarbonyl)-4-(phenylamino)piperidine-4-carboxylic acid is a chemical compound with the molecular formula C17H24N2O4. It is a piperidine derivative that contains a tert-butoxycarbonyl protecting group and a phenylamino group. 1-(tert-butoxycarbonyl)-4-(phenylaMino)piperidine-4-carboxylic acid is important in the field of medicinal chemistry and drug development, and its precise synthesis and properties make it valuable for various research and practical applications.
Uses
Used in Pharmaceutical Synthesis:
1-(tert-butoxycarbonyl)-4-(phenylamino)piperidine-4-carboxylic acid is used as a key intermediate in the synthesis of pharmaceuticals and organic compounds. The tert-butoxycarbonyl protecting group is often used to protect amine functional groups during chemical reactions, while the phenylamino group adds aromatic properties to the molecule.
Used in Medicinal Chemistry Research:
1-(tert-butoxycarbonyl)-4-(phenylamino)piperidine-4-carboxylic acid is used as a research compound in medicinal chemistry. Its unique structure and properties make it valuable for studying the interactions between molecules and their biological targets, as well as for the development of new drugs and therapies.
Used in Drug Development:
1-(tert-butoxycarbonyl)-4-(phenylamino)piperidine-4-carboxylic acid is used in drug development to create new pharmaceuticals with specific therapeutic properties. Its versatility and the ability to modify its structure make it a promising candidate for the development of novel drugs with improved efficacy and safety profiles.
Check Digit Verification of cas no
The CAS Registry Mumber 1159835-31-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,5,9,8,3 and 5 respectively; the second part has 2 digits, 3 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1159835-31:
(9*1)+(8*1)+(7*5)+(6*9)+(5*8)+(4*3)+(3*5)+(2*3)+(1*1)=180
180 % 10 = 0
So 1159835-31-0 is a valid CAS Registry Number.
1159835-31-0Relevant articles and documents
FENTANYL HAPTENS, FENTANYL HAPTEN CONJUGATES, AND METHODS FOR MAKING AND USING
-
Page/Page column 73; 82; 83, (2021/09/17)
This disclosure describes fentanyl haptens, a fentanyl hapten-carrier conjugate, methods of making the fentanyl hapten-carrier conjugate, and methods of using the fentanyl hapten-carrier conjugate including, for example, as a prophylactic vaccine to counteract toxicity from exposure to fentanyl, fentanyl derivatives, and fentanyl analogs. In some embodiments, the fentanyl hapten-carrier conjugate or a composition including the fentanyl hapten-carrier conjugate may be used in an anti-opioid vaccine.
Preparation method of alfentanil and sufentan and compounds used for preparation of sufentanil and alfentan
-
Paragraph 0178; 0179; 0180; 0181, (2017/06/02)
The invention discloses a preparation method of alfentanil and sufentan and compounds used for preparation of sufentanil and alfentan. Specifically, the method for preparation of a compound shown as formula V includes: carrying out BOC reaction on a compound shown as formula IV to obtain the compound shown as formula V in the specification. The method can conveniently, efficiently and safely prepare an intermediate product for synthesis of alfentanil and sufentan, i.e. the compound shown as formula V. And then, the compound shown as formula V can be effectively used for preparation of alfentanil and sufentan.
SUBSTITUTED SPIROCYDIC INHIBITORS OF AUTOTAXIN
-
Page/Page column 176; 177, (2015/11/17)
The present invention relates to compounds according to Formula 1 and pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancer, lymphocyte homing, chronic inflammation, neuropathic pain, fibrotic diseases, thrombosis, and cholestatic pruritus, mediated at least in part by ATX.
